ArticleCancer medicine2026
Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population-Based Study in Japan.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Owing to improved prognosis, cancer survivors are a growing population; however, little is known about their prevalence in Asian countries. This study estimated the prevalence and characteristics of cancer survivors in Japan, including long-term survivors. Using data from the Osaka Cancer Registry, which covers 8.8 million residents in Osaka Prefecture, Japan, we identified individuals diagnosed with cancer between 1975 and 2019 who were alive in 2019. Cancer prevalence was calculated as the number of patients alive in 2019, stratified by sex, age in 2019, time since diagnosis, and 22 cancer types. National estimates were obtained by applying sex- and age-specific prevalence proportions in Osaka to the Japanese population. In 2019, 461,489 cancer survivors were living in Osaka Prefecture (5.4% of the prefectural population; 5221 per 100,000). Most were older adults, with 83% of males (n = 188,881) and 70% of females (n = 163,331) aged ≥ 65 years in 2019. Long-term survivors (≥ 10 years after diagnosis) comprised 34% of all survivors. These patterns varied across cancer types. Nationally, an estimated 6.9 million individuals (5.5% of the national population) lived after a cancer diagnosis. Based on 44 years of follow-up data, our findings highlighted a substantial subgroup of cancer survivors requiring long-term treatment, follow-up care, and age-specific support. These findings may provide useful insights for healthcare planning and cancer survivor policies in aging societies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.